206 related articles for article (PubMed ID: 26926928)
1. Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.
Sanchez A; Schoenfeld JD; Nguyen PL; Fiorentino M; Chowdhury D; Stampfer MJ; Sesso HD; Giovannucci E; Mucci LA; Shui IM
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):197-201. PubMed ID: 26926928
[TBL] [Abstract][Full Text] [Related]
2. Replication of a genetic variant for prostate cancer-specific mortality.
Penney KL; Shui IM; Feng Z; Sesso HD; Stampfer MJ; Stanford JL
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):260-3. PubMed ID: 25939514
[TBL] [Abstract][Full Text] [Related]
3. GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis.
Margalit DN; Jordahl KM; Werner L; Wang X; Gwo-Shu Lee M; Penney KL; Batista JL; Martin NE; Chan JM; Kantoff PW; Stampfer MJ; Nguyen PL; Mucci LA
Clin Genitourin Cancer; 2015 Aug; 13(4):370-377.e1. PubMed ID: 25662905
[TBL] [Abstract][Full Text] [Related]
4. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer.
Stopsack KH; Gerke T; Zareba P; Pettersson A; Chowdhury D; Ebot EM; Flavin R; Finn S; Kantoff PW; Stampfer MJ; Loda M; Fiorentino M; Mucci LA
Carcinogenesis; 2020 Jul; 41(7):904-908. PubMed ID: 32556091
[TBL] [Abstract][Full Text] [Related]
5. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
[TBL] [Abstract][Full Text] [Related]
6. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.
Schoenfeld JD; Margalit DN; Kasperzyk JL; Shui IM; Rider JR; Epstein MM; Meisner A; Kenfield SA; Martin NE; Nguyen PL; Kantoff PW; Giovannucci EL; Stampfer MJ; Mucci LA
Clin Cancer Res; 2013 Mar; 19(6):1612-9. PubMed ID: 23382116
[TBL] [Abstract][Full Text] [Related]
7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
8. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality.
Shui IM; Stark JR; Penney KL; Schumacher FR; Epstein MM; Pitt MJ; Stampfer MJ; Tamimi RM; Lindstrom S; Sesso HD; Fall K; Ma J; Kraft P; Giovannucci E; Mucci LA
Prostate; 2012 Feb; 72(2):209-16. PubMed ID: 21563195
[TBL] [Abstract][Full Text] [Related]
11. α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study.
Barry M; Dhillon PK; Stampfer MJ; Perner S; Ma J; Giovannucci E; Kurth T; Mucci LA; Rubin MA
Prostate; 2012 Feb; 72(3):301-6. PubMed ID: 21713964
[TBL] [Abstract][Full Text] [Related]
12. Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival.
Van Blarigan EL; Ma J; Kenfield SA; Stampfer MJ; Sesso HD; Giovannucci EL; Witte JS; Erdman JW; Chan JM; Penney KL
Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):1037-46. PubMed ID: 24711484
[TBL] [Abstract][Full Text] [Related]
13. Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study.
Margalit DN; Kasperzyk JL; Martin NE; Sesso HD; Gaziano JM; Ma J; Stampfer MJ; Mucci LA
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):28-32. PubMed ID: 22079732
[TBL] [Abstract][Full Text] [Related]
14. Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
Downer MK; Kenfield SA; Stampfer MJ; Wilson KM; Dickerman BA; Giovannucci EL; Rimm EB; Wang M; Mucci LA; Willett WC; Chan JM; Van Blarigan EL
J Clin Oncol; 2019 Jun; 37(17):1499-1511. PubMed ID: 31026211
[TBL] [Abstract][Full Text] [Related]
15. BCL2 genotypes and prostate cancer survival.
Renner W; Langsenlehner U; Krenn-Pilko S; Eder P; Langsenlehner T
Strahlenther Onkol; 2017 Jun; 193(6):466-471. PubMed ID: 28396899
[TBL] [Abstract][Full Text] [Related]
16. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of BRCA1 and lethal prostate cancer.
Fiorentino M; Judson G; Penney K; Flavin R; Stark J; Fiore C; Fall K; Martin N; Ma J; Sinnott J; Giovannucci E; Stampfer M; Sesso HD; Kantoff PW; Finn S; Loda M; Mucci L
Cancer Res; 2010 Apr; 70(8):3136-9. PubMed ID: 20388772
[TBL] [Abstract][Full Text] [Related]
19. Common variation in the BRCA1 gene and prostate cancer risk.
Douglas JA; Levin AM; Zuhlke KA; Ray AM; Johnson GR; Lange EM; Wood DP; Cooney KA
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1510-6. PubMed ID: 17585057
[TBL] [Abstract][Full Text] [Related]
20. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
